Over the last decade, treatments for the blood cancer myeloma have come on in leaps and bounds – but it remains incurable and unpredictable for individual patients and clinicians.<
This year’s eyeforpharma Barcelona conference might have seemed all doom and gloom at the outset, with many predicting the downfall of pharma as we know it – but there were plenty of speake
The information age has produced a generation of young people concerned about their health, but distrustful of big brands – and that includes the pharmaceutical industry.
To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unme
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
